Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Indoles
  • Neoplasms

abstract

  • Ro 31-7453 was well tolerated, with manageable adverse effects. Significant PK variability (absorption, metabolism, and excretion) was observed, and a substantial number of additional patients are needed to confirm the recommended phase II dose. Additional pharmacology and phase II studies are under way to explore the dose-toxicity relationship.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.12.007

PubMed ID

  • 15310782

Additional Document Info

start page

  • 3366

end page

  • 74

volume

  • 22

number

  • 16